SAM
CODX

Smartleaf Asset Management’s Co-Diagnostics CODX Stock Holding History

Smartleaf Asset Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$396 Hold
133
– – ﹤0.01% 3232
2026
Q1 		$226 Hold
133
– – ﹤0.01% 3322
2025
Q4 		$723 Buy
+133
New +$1.45K ﹤0.01% 3216

Other funds holding CODX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAG
Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Smartleaf Asset Management's CODX Position: Q2 2026 in Review

Smartleaf Asset Management held its Co-Diagnostics (CODX) position steady in Q2 2026 at 133 shares worth $396. The position accounts for ﹤0.01% of the portfolio, ranked #3232.

Smartleaf Asset Management first reported a position in CODX in Q4 2025 and has held it in 3 quarters since. The position peaked at $723 in Q4 2025. 24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

  • Smartleaf Asset Management held 133 shares of Co-Diagnostics worth $396 as of Q2 2026.
  • Smartleaf Asset Management left its Co-Diagnostics share count unchanged in Q2 2026.
  • Co-Diagnostics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3232 holding.
  • Smartleaf Asset Management first reported a position in Co-Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Co-Diagnostics position peaked at $723 in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.